{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:20:41Z","timestamp":1790036441783,"version":"4.0.1"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01517","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T16:32:38Z","timestamp":1546965158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":74,"title":["Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk"],"prefix":"10.3389","volume":"9","author":[{"given":"Yangli","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinqiu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jbmr.3063","article-title":"A mendelian randomization study of the effect of type-2 diabetes and glycemic traits on bone mineral density.","volume":"32","author":"Ahmad","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.","volume":"5","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin.","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study.","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"key":"B5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1210\/jc.2010-0226","article-title":"High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus.","volume":"95","author":"Burghardt","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1359\/jbmr.060507","article-title":"Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women.","volume":"21","author":"Burnett","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.20945\/2359-3997000000039","article-title":"Relationship between adiponectin and leptin on osteocalcin in obese adolescents during weight loss therapy.","volume":"62","author":"Campos","year":"2018","journal-title":"Arch. Endocrinol. Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control.","volume":"32","author":"Chao","year":"2014","journal-title":"Clin. Diabetes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.2215\/CJN.10391012","article-title":"Proximal tubule function and response to acidosis.","volume":"9","author":"Curthoys","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the american diabetes association (ada) and the european association for the study of diabetes (EASD).","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.","volume":"16","author":"Fadini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jbmr.2106","article-title":"In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.","volume":"29","author":"Farr","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s001250051248","article-title":"Diabetes mellitus and the incidence of hip fracture: results from the nord-trondelag health survey.","volume":"42","author":"Forsen","year":"1999","journal-title":"Diabetologia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes.","volume":"377","author":"Garg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.2337\/dc12-2673","article-title":"Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.","volume":"11","author":"Haring","year":"2013","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cca.2006.03.017","article-title":"Glycation endproducts in osteoporosis \u2014 is there a pathophysiologic importance?","volume":"371","author":"Hein","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"B18","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1530\/EJE-16-0652","article-title":"Mechanisms in endocrinology: diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis.","volume":"176","author":"Hygum","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/jbmr.5650100709","article-title":"Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells.","volume":"10","author":"Inaba","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/1479164116657304","article-title":"Tofogliflozin, a selective inhibitor of sodium-glucose transport 2, suppresses renal damage in KKAy\/Ta mice, obese and type 2 diabetic animals.","volume":"13","author":"Ishibashi","year":"2016","journal-title":"Diab. Vasc. Dis. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1073\/pnas.1715687114","article-title":"Body weight homeostat that regulates fat mass independently of leptin in rats and mice.","volume":"115","author":"Jansson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/dom.12898","article-title":"Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial.","volume":"19","author":"Kadowaki","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.","volume":"4","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s12325-017-0573-0","article-title":"Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase i\u2013iii clinical trials.","volume":"34","author":"Kohler","year":"2017","journal-title":"Adv. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the cvd-real study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors).","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus.","volume":"8","author":"Kovacs","year":"2015","journal-title":"Clin. Ther."},{"key":"B27","first-page":"775","article-title":"Bone loss and bone turnover in diabetes.","volume":"44","author":"Krakauer","year":"1995","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1007\/s00198-016-3656-x","article-title":"Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study.","volume":"27","author":"Laurent","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1002\/jbmr.1759","article-title":"Type 2 diabetes and bone.","volume":"27","author":"Leslie","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"31302","DOI":"10.18632\/oncotarget.23937","article-title":"The association between risk of limb fracture and type 2 diabetes mellitus.","volume":"9","author":"Liu","year":"2018","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1503\/cmaj.080486","article-title":"Longterm use of thiazolidinediones and fractures in type 2 diabetes: a metaanalysis.","volume":"1","author":"Loke","year":"2009","journal-title":"CAMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1210\/jc.2012-1546","article-title":"Circulating osteogenic precursor cells in type 2 diabetes mellitus.","volume":"97","author":"Manavalan","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1210\/er.2009-0024","article-title":"From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis.","volume":"3","author":"Manolagas","year":"2010","journal-title":"Endocr. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00774-013-0508-z","article-title":"Role of local vitamin D signaling and cellular calcium transport system in bone homeostasis.","volume":"32","author":"Masuyama","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2015.04.026","article-title":"Effects of diabetes drugs on the skeleton.","volume":"82","author":"Meier","year":"2016","journal-title":"Bone"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.jcte.2013.12.001","article-title":"Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.","volume":"1","author":"Napolitano","year":"2014","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.","volume":"38","author":"Neal","year":"2015","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/jbmr.3057","article-title":"Type 2 diabetes mellitus is associated with better bone microarchitecture but lower bone material strength and poorer physical function in elderly women: a population-based study.","volume":"32","author":"Nilsson","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jcem.82.9.4258","article-title":"Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover.","volume":"82","author":"Okazaki","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1359\/jbmr.090725","article-title":"Bone mass and strength in older men with type 2 diabetes: the Osteoporotic fractures in men study.","volume":"25","author":"Petit","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0511-0","article-title":"Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.","volume":"16","author":"Pfeifer","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2011.218","article-title":"Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.","volume":"8","author":"Quarles","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.","volume":"140","author":"Radholm","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF02561404","article-title":"Suggestion of a deficient osteoblastic function in diabetes mellitus: the possible cause of osteopenia in diabetics.","volume":"45","author":"Rico","year":"1989","journal-title":"Calcif. Tissue Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebocontrolled, phase 3 trial.","volume":"3","author":"Roden","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.","volume":"7","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1007\/s00198-006-0155-5","article-title":"Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN\/Kob rats.","volume":"17","author":"Saito","year":"2006","journal-title":"Osteoporos. Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00198-009-1066-z","article-title":"Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.","volume":"21","author":"Saito","year":"2010","journal-title":"Osteoporos. Int."},{"key":"B54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/DMSO.S116243","article-title":"Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.","volume":"9","author":"Scheerer","year":"2016","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1210\/jc.2015-1215","article-title":"Effects of TZD use and discontinuation on fracture rates in ACCORD bone study.","volume":"100","author":"Schwartz","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1359\/JBMR.041219","article-title":"Diabetes and bone loss at the hip in older black and white adults.","volume":"20","author":"Schwartz","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009417","article-title":"SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta analysis.","volume":"2","author":"Shyangdan","year":"2016","journal-title":"BMJ Open"},{"key":"B58","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial.","volume":"40","author":"Softeland","year":"2017","journal-title":"Diabetes Care"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2014.20","article-title":"Tofogliflozin, a sodium\/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.","volume":"4","author":"Suzuki","year":"2014","journal-title":"Nutr. Diabetes"},{"key":"B60","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.metabol.2006.12.008","article-title":"Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus.","volume":"5","author":"Tamura","year":"2007","journal-title":"Metabolism"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone.","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","article-title":"SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice.","volume":"82","author":"Thrailkill","year":"2016","journal-title":"Bone"},{"key":"B64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bone.2016.10.026","article-title":"The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.","volume":"94","author":"Thrailkill","year":"2017","journal-title":"Bone"},{"key":"B65","year":"2016","journal-title":"FDA Drug Safety Communication: FDA Revises Label of Diabetes Drug Canagliflozin (Invokana, Invokamet) to Include Updates on Bone Fracture Risk and New Information on Decreased Bone Mineral Density"},{"key":"B66","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis.","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos. Int."},{"key":"B67","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus.","volume":"101","author":"Watts","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B68","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.","volume":"16","author":"Weir","year":"2014","journal-title":"J. Clin. Hypertens."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1210\/en.2008-1639","article-title":"In vitro and in vivo effects of adiponectin on bone.","volume":"8","author":"Williams","year":"2009","journal-title":"Endocrinology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2146\/ajhp160319","article-title":"Fracture risk associated with common medications used in treating type 2 diabetes mellitus.","volume":"74","author":"Wolverton","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.10.003","article-title":"Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus.","volume":"39","author":"Yale","year":"2017","journal-title":"Clin. Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00198-014-2927-7","article-title":"Defects in cortical microarchitecture among African-American women with type 2 diabetes.","volume":"26","author":"Yu","year":"2015","journal-title":"Osteoporos. Int."},{"key":"B73","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B74","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.diabres.2010.09.013","article-title":"Prevalence and predictors of osteopenia and osteoporosis in postmenopausal Chinese women with type 2 diabetes.","volume":"90","author":"Zhou","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B75","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials.","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/jbmr.2564","article-title":"Does diet-induced weight loss lead to bone loss in overweight or obese adults? a systematic review and meta-analysis of clinical trials.","volume":"30","author":"Zibellini","year":"2015","journal-title":"J. Bone Miner. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01517\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T12:56:47Z","timestamp":1547816207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01517\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":76,"alternative-id":["10.3389\/fphar.2018.01517"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01517","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"article-number":"1517"}}